Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHA) EPS (Weighted Average and Diluted) (2018 - 2025)

Historic EPS (Weighted Average and Diluted) for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to -$90496.0.

  • Innate Pharma's EPS (Weighted Average and Diluted) fell 1569.04% to -$90496.0 in Q2 2025 from the same period last year, while for Jun 2025 it was -$90496.0, marking a year-over-year decrease of 1569.04%. This contributed to the annual value of -$0.65 for FY2024, which is 57315.11% down from last year.
  • Per Innate Pharma's latest filing, its EPS (Weighted Average and Diluted) stood at -$90496.0 for Q2 2025, which was down 1569.04% from -$78222.6 recorded in Q2 2024.
  • Innate Pharma's EPS (Weighted Average and Diluted)'s 5-year high stood at $28400.0 during Q2 2023, with a 5-year trough of -$90496.0 in Q2 2025.
  • In the last 5 years, Innate Pharma's EPS (Weighted Average and Diluted) had a median value of -$912.5 in 2022 and averaged -$28246.2.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first tumbled by 115365469.72% in 2022, then surged by 321232.88% in 2023.
  • Innate Pharma's EPS (Weighted Average and Diluted) (Quarter) stood at $0.08 in 2021, then tumbled by 1153654.7% to -$912.5 in 2022, then surged by 3212.33% to $28400.0 in 2023, then crashed by 375.43% to -$78222.6 in 2024, then fell by 15.69% to -$90496.0 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$90496.0 in Q2 2025, compared to -$78222.6 in Q2 2024 and $28400.0 in Q2 2023.